FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317233423> ?p ?o ?g. }

• W4317233423 endingPage "220" @default.
• W4317233423 startingPage "213" @default.
• W4317233423 abstract "HDCT and peripheral-blood stem-cell transplant (PBSCT) can cure up to 60% of pts with relapsed mGCT. Maintenance daily oral etoposide after salvage therapy has demonstrated potential clinical benefit. We now evaluate the potential role of maintenance etoposide versus observation post HDCT+PBSCT in this nonrandomized retrospective analysis.The prospectively maintained Indiana University testicular cancer database was interrogated. Patients with relapsed non-seminoma who completed HDCT+PBSCT and achieved complete serologic remission and hematologic recovery were evaluated. Outcomes of pts who received maintenance etoposide (N = 141) were compared to pts who were observed (N = 242). In this retrospective study, Kaplan-Meier method was used to analyze progression-free survival (PFS) and overall survival (OS). Univariable and multivariable cox regression models were used to determine variables associated with PFS. We also performed an additional analysis to compare the survival outcomes in the platinum-refractory patients' subgroup based on maintenance etoposide treatment.Two-year PFS in the maintenance etoposide vs observation group was 55% vs. 46% (P = .028). Two-year OS was 61% vs 54% (P = .04). A multivariable analysis was performed, including the factors: primary tumor site (testis vs. mediastinum), IGCCCG risk, platinum refractory, HDCT line of therapy (2nd vs ≥3rd), tumor marker amplitude at HDCT initiation, and receipt of maintenance etoposide post HDCT vs. observation. Maintenance etoposide was confirmed as an independent predictor of improved PFS with HR 0.51 [95% CI, 0.37-0.70] (P < .001). Two-year OS and PFS for platinum-refractory patients who received maintenance etoposide vs. observation group were 50.2% vs. 26.1% (P < .0001) and 44.2% vs.. 23.1% (P = .0003), respectively. There was no statistically significant difference in 2-year OS and PFS between the platinum-sensitive patients who received maintenance etoposide and those who were observed.Daily oral etoposide therapy produced encouraging efficacy results in patients with relapsed non-seminoma GCT (NSGCT) who completed HDCT and PBSCT and achieved complete serologic remission and hematologic recovery. Patients with platinum-refractory disease and poor prognostic features are potential candidates for daily maintenance oral etoposide post HDCT. These data have led to an ongoing randomized phase II clinical trial (NCT04804007)." @default.
• W4317233423 created "2023-01-18" @default.
• W4317233423 creator A5018335096 @default.
• W4317233423 creator A5019054264 @default.
• W4317233423 creator A5047486042 @default.
• W4317233423 creator A5048660181 @default.
• W4317233423 creator A5053079426 @default.
• W4317233423 creator A5066632494 @default.
• W4317233423 creator A5069649180 @default.
• W4317233423 creator A5074428655 @default.
• W4317233423 creator A5080410100 @default.
• W4317233423 date "2023-04-01" @default.
• W4317233423 modified "2023-10-01" @default.
• W4317233423 title "Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT)" @default.
• W4317233423 cites W1543697093 @default.
• W4317233423 cites W1880291741 @default.
• W4317233423 cites W1884032213 @default.
• W4317233423 cites W1955033393 @default.
• W4317233423 cites W1958308805 @default.
• W4317233423 cites W1968052792 @default.
• W4317233423 cites W1970285471 @default.
• W4317233423 cites W1978515323 @default.
• W4317233423 cites W1980324865 @default.
• W4317233423 cites W2042770658 @default.
• W4317233423 cites W2074177582 @default.
• W4317233423 cites W2074643584 @default.
• W4317233423 cites W2102925522 @default.
• W4317233423 cites W2130387174 @default.
• W4317233423 cites W2138435494 @default.
• W4317233423 cites W2152960203 @default.
• W4317233423 cites W2163130660 @default.
• W4317233423 cites W2333426429 @default.
• W4317233423 cites W2555626407 @default.
• W4317233423 cites W2765537501 @default.
• W4317233423 cites W2767541388 @default.
• W4317233423 cites W44254208 @default.
• W4317233423 doi "https://doi.org/10.1016/j.clgc.2023.01.004" @default.
• W4317233423 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36737276" @default.
• W4317233423 hasPublicationYear "2023" @default.
• W4317233423 type Work @default.
• W4317233423 citedByCount "1" @default.
• W4317233423 countsByYear W43172334232023 @default.
• W4317233423 crossrefType "journal-article" @default.
• W4317233423 hasAuthorship W4317233423A5018335096 @default.
• W4317233423 hasAuthorship W4317233423A5019054264 @default.
• W4317233423 hasAuthorship W4317233423A5047486042 @default.
• W4317233423 hasAuthorship W4317233423A5048660181 @default.
• W4317233423 hasAuthorship W4317233423A5053079426 @default.
• W4317233423 hasAuthorship W4317233423A5066632494 @default.
• W4317233423 hasAuthorship W4317233423A5069649180 @default.
• W4317233423 hasAuthorship W4317233423A5074428655 @default.
• W4317233423 hasAuthorship W4317233423A5080410100 @default.
• W4317233423 hasConcept C126322002 @default.
• W4317233423 hasConcept C141071460 @default.
• W4317233423 hasConcept C143998085 @default.
• W4317233423 hasConcept C167135981 @default.
• W4317233423 hasConcept C2776694085 @default.
• W4317233423 hasConcept C2776938808 @default.
• W4317233423 hasConcept C2778119113 @default.
• W4317233423 hasConcept C2778239845 @default.
• W4317233423 hasConcept C2778283404 @default.
• W4317233423 hasConcept C2780775027 @default.
• W4317233423 hasConcept C2781451048 @default.
• W4317233423 hasConcept C71924100 @default.
• W4317233423 hasConceptScore W4317233423C126322002 @default.
• W4317233423 hasConceptScore W4317233423C141071460 @default.
• W4317233423 hasConceptScore W4317233423C143998085 @default.
• W4317233423 hasConceptScore W4317233423C167135981 @default.
• W4317233423 hasConceptScore W4317233423C2776694085 @default.
• W4317233423 hasConceptScore W4317233423C2776938808 @default.
• W4317233423 hasConceptScore W4317233423C2778119113 @default.
• W4317233423 hasConceptScore W4317233423C2778239845 @default.
• W4317233423 hasConceptScore W4317233423C2778283404 @default.
• W4317233423 hasConceptScore W4317233423C2780775027 @default.
• W4317233423 hasConceptScore W4317233423C2781451048 @default.
• W4317233423 hasConceptScore W4317233423C71924100 @default.
• W4317233423 hasIssue "2" @default.
• W4317233423 hasLocation W43172334231 @default.
• W4317233423 hasLocation W43172334232 @default.
• W4317233423 hasOpenAccess W4317233423 @default.
• W4317233423 hasPrimaryLocation W43172334231 @default.
• W4317233423 hasRelatedWork W2025538838 @default.
• W4317233423 hasRelatedWork W2049680018 @default.
• W4317233423 hasRelatedWork W2120734114 @default.
• W4317233423 hasRelatedWork W2406687475 @default.
• W4317233423 hasRelatedWork W2600735778 @default.
• W4317233423 hasRelatedWork W2789166760 @default.
• W4317233423 hasRelatedWork W2805901899 @default.
• W4317233423 hasRelatedWork W4213321885 @default.
• W4317233423 hasRelatedWork W4310946033 @default.
• W4317233423 hasRelatedWork W2133000900 @default.
• W4317233423 hasVolume "21" @default.
• W4317233423 isParatext "false" @default.
• W4317233423 isRetracted "false" @default.
• W4317233423 workType "article" @default.